Entity

Time filter

Source Type


Bao W.,Shanghai JiaoTong University | Liu P.,Shanghai JiaoTong University | Qiu Z.,Tongji University | Yu L.,Tongji University | And 3 more authors.
Chinese Medical Journal | Year: 2015

Background: The efficacy of montelukast (MONT), a cysteinyl leukotriene receptor antagonist, in nonasthmatic eosinophilic bronchitis (NAEB), especially its influence on cough associated life quality is still indefinite. We evaluated the efficacy of MONT combined with budesonide (BUD) as compared to BUD monotherapy in improving life quality, suppressing airway eosinophilia and cough remission in NAEB. Methods: A prospective, open-labeled, multicenter, randomized controlled trial was conducted. Patients with NAEB (aged 18-75 years) were randomized to inhaled BUD (200 μg, bid) or BUD plus oral MONT (10 μg, qn) for 4 weeks. Leicester cough questionnaire (LCQ) life quality scores, cough visual analog scale (CVAS) scores, eosinophil differential ratio (Eos), and eosinophil cationic protein (ECP) in induced sputum were monitored and compared. Results: The control and MONT groups contained 33 and 32 patients, respectively, with similar baseline characteristics. Significant with-in group improvement in CVAS, LCQ scores, Eos, and ECP was observed in both groups during treatment. After 2-week treatment, add-on treatment of MONT was significantly more effective than BUD monotherapy for CVAS decrease and LCQ scores improvement (both P < 0.05). Similar results were seen at 4-week assessment (both P < 0.05). 4-week add-on therapy of MONT also resulted in a higher percentage of patients with normal sputum Eos (<2.5%) and greater decrease of ECP (both P < 0.05). Conclusions: MONT combined with BUD was demonstrated cooperative effects in improvement of life quality, suppression of eosinophilic inflammation, and cough remission in patients with NAEB. © 2015 Chinese Medical Association. All rights reserved.


Sheng Q.,Shanghai Putuo Peoples Hospital | Jin Y.-J.,Shanghai Putuo Peoples Hospital | Zhu J.-H.,Shanghai Putuo Peoples Hospital | Yao X.-X.,Shanghai Putuo Peoples Hospital | And 3 more authors.
Tumor | Year: 2011

Objective: To observe the effects of endogenic field hyperthermia combined with intraperitoneal chemotherapy on the treatment outcomes and serum tumor markers [tumor supplied group of factors (TSGF), carcinoembryonic antigen (CEA) and CA50] of patients with advanced gastric cancer and celiac lymph node metastasis. Methods: Sixty patients with stage IIIB-IV gastric cancer and celiac lymph node metastasis were recruited between October 2006 and December 2009, and then they were randomly divided into two groups, including intraperitoneal chemotherapy group [ n=30, treated with intraperitoneal chemotherapy (adriamycin) ] and hyperthermic intraperitoneal chemotherapy group (n=30, treated with endogenic field hyperthermia combined with intraperitoneal chemotherapy). The short-term response, overall survival, adverse reactions, and the changes of serum TSGF, CEA and CA50 levels before and after treatment were evaluated. Results: After 8 weeks of treatment, the total response rates of the intraperitoneal chemotherapy group and the hyperthermic intraperitoneal chemotherapy group were 63.3% (19/30) and 90.0% (27/30), respectively, and the difference between the two groups was significant ( P<0.01). The one-year survival rate in the hyperthermic intraperitoneal chemotherapy group was higher than that in the intraperitoneal chemotherapy group [73.3% (22/30) vs 50.0% (15/30), P<0.01]. After treatment, there was a more significant decrease in serum TSGF, CEA and CA50 levels in the hyperthermic intraperitoneal chemotherapy group as compared with that in the intraperitoneal chemotherapy group ( P<0.01). The rates of adverse reactions in these two groups were similar. Conclusion: Endogenic field hyperthermia combined with intraperitoneal chemotherapy is an effective treatment for patients with gastric cancer and celiac lymph node metastasis. Serum TSGF, CEA and CA50 may be considered as some of the measurements to monitor the efficacy of hyperthermic chemotherapy. Copyright© 2011 by TUMOR.

Discover hidden collaborations